Sarepta Therapeutics | SRPT - Sales Revenues


Sarepta Therapeutics reported $730.8M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Daiichi Sankyo JPY 587B 28.89B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Insmed USD 305.96M 42.16M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
Moderna USD 389M 289M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026